Terns Pharmaceuticals Reports Positive Data on Leukemia Drug

Dow Jones12-09

By Katherine Hamilton

Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up.

The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular response rate in a Phase 1 trial of patients with chronic myeloid leukemia.

Shares gained 35% to $39.42, at one point hitting an all-time high of $45. The stock has jumped nearly eightfold this year.

The major molecular response rate was 75% over 24 weeks at doses of 320 milligrams and above. That data, along with a strong safety profile, supports selection of 320 milligrams and 500 milligrams as the recommended Phase 2 doses, Terns said.

Study enrollment has also increased, which supports advancing TERN-701 through dose expansion cohorts and the initiation of studies.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 08, 2025 15:40 ET (20:40 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590363778?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590363778","market":"sh","top_or_hot":-1,"title":"Terns Pharmaceuticals Reports Positive Data on Leukemia Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up. \n</p>\n<p>\n  The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular response rate in a Phase 1 trial of patients with chronic myeloid leukemia. \n</p>\n<p>\n  Shares gained 35% to $39.42, at one point hitting an all-time high of $45. The stock has jumped nearly eightfold this year. \n</p>\n<p>\n  The major molecular response rate was 75% over 24 weeks at doses of 320 milligrams and above. That data, along with a strong safety profile, supports selection of 320 milligrams and 500 milligrams as the recommended Phase 2 doses, Terns said. \n</p>\n<p>\n  Study enrollment has also increased, which supports advancing TERN-701 through dose expansion cohorts and the initiation of studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 15:40 ET (20:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Reports Positive Data on Leukemia Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Reports Positive Data on Leukemia Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-09 04:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up. \n</p>\n<p>\n  The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular response rate in a Phase 1 trial of patients with chronic myeloid leukemia. \n</p>\n<p>\n  Shares gained 35% to $39.42, at one point hitting an all-time high of $45. The stock has jumped nearly eightfold this year. \n</p>\n<p>\n  The major molecular response rate was 75% over 24 weeks at doses of 320 milligrams and above. That data, along with a strong safety profile, supports selection of 320 milligrams and 500 milligrams as the recommended Phase 2 doses, Terns said. \n</p>\n<p>\n  Study enrollment has also increased, which supports advancing TERN-701 through dose expansion cohorts and the initiation of studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 15:40 ET (20:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590363778","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590363778","pubTimestamp":1765226400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up.The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular response rate in a Phase 1 trial of patients with chronic myeloid leukemia.Shares gained 35% to $39.42, at one point hitting an all-time high of $45. The stock has jumped nearly eightfold this year.The major molecular response rate was 75% over 24 weeks at doses of 320 milligrams and above. That data, along with a strong safety profile, supports selection of 320 milligrams and 500 milligrams as the recommended Phase 2 doses, Terns said.Study enrollment has also increased, which supports advancing TERN-701 through dose expansion cohorts and the initiation of studies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"Terns制药公司报告白血病药物的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up. \n\n\n  The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular response rate in a Phase 1 trial of patients with chronic myeloid leukemia. \n\n\n  Shares gained 35% to $39.42, at one point hitting an all-time high of $45. The stock has jumped nearly eightfold this year. \n\n\n  The major molecular response rate was 75% over 24 weeks at doses of 320 milligrams and above. That data, along with a strong safety profile, supports selection of 320 milligrams and 500 milligrams as the recommended Phase 2 doses, Terns said. \n\n\n  Study enrollment has also increased, which supports advancing TERN-701 through dose expansion cohorts and the initiation of studies. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 15:40 ET (20:40 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590363778","isCrawlerRequest":true}